Health Benefits of Repeated Treatment in Pediatric Schistosomiasis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Objective and Hypotheses: This project has the overall objective of implementing and evaluating new approaches to reducing the current and future burden of urinary schistosomiasis in young children using the antihelminthic drug praziquantel. The investigators hypotheses are that (1) praziquantel treatment will be as effective in children 1 to 5 years of age (who are routinely excluded from schistosomiasis control programmes) as it is in older 6-10 year old children and (2) two treatments will be more effective than a single treatment, especially in children 1 to 5 years of age.
| Condition |
|---|
|
Schistosomiasis |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Health Benefits of Repeated Treatment in Pediatric Schistosomiasis |
- Change from baseline in schistosome-specific and systemic immune responses [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]Determine the change at 6 weeks post antihelminthic treatment from baseline of schistosome-specific and systemic immune responses
- Change from baseline in schistosome-specific and systemic immune responses [ Time Frame: 12 months ] [ Designated as safety issue: No ]Determine the change at 12 months post antihelminthic treatment from baseline of schistosome-specific and systemic immune responses. Determine the effects of single and double antihelminthic treatments on these immunological changes.
- Change from baseline in schistosome-related morbidity and disease markers [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]Determine the change in prevalance and magnitude of schistosome-related disease and morbidity markers at 6 weeks from those at baseline.
- Change from baseline in morbidity and disease markers [ Time Frame: 12 months ] [ Designated as safety issue: No ]Determine the change in prevalance and magnitude of schistosome-related disease and morbidity markers at 12 months from those at baseline. Determine the effects of single and double antihelminthic treatments on the disease and morbidity measures.
| Estimated Enrollment: | 700 |
| Study Start Date: | February 2012 |
| Estimated Study Completion Date: | November 2014 |
| Estimated Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
This study aims to address the present health inequity by refinement of an existing drug regimen to improve the current and future health of pre-school children and infants. Praziquantel is cheap, highly efficacious and safe, presenting a realistic opportunity of using a pre-existing tool in a modified way to benefit child health and development. The study will focus on children aged 1 to 10 years of age, comparing the impact of single vs. double treatment with PZQ on the current and future health status of the children. The immediate health benefits of PZQ treatment in children aged 6-10 years of age have already been documented and therefore by including 6-10 year olds in the proposed study, we can determine if the effects of PZQ treatment on health and morbidity measures is age dependent. By killing worms PZQ stops the morbidity related to the presence of worms and eggs such as anaemia, abdominal pain, diarrhoea and blood in the urine. Therefore the study will investigate the immediate health benefits of treating pre-school children and infants.
Eligibility| Ages Eligible for Study: | 1 Year to 10 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Zimbabwean children
Inclusion Criteria:
- lifelong residents of the area
- have provided at least 2 urine and 2 stool for parasitological examination
- have given a blood sample before and after each treatment episode
- be negative for hookworm, Trichuris and Ascaris
Exclusion Criteria:
- clinical signs of tuberculosis or malaria
- presenting with fever
- have had a recent major operation, illness or vaccination
- have previously received antihelminthic treatment
Contacts and Locations| Contact: Nicholas Midzi | midzinicholas@yahoo.com |
| Zimbabwe | |
| National Institutes for Health Research | Not yet recruiting |
| Harare, Zimbabwe | |
| Contact: Nicholas Midzi, PhD midzinicholas@yahoo.com | |
| Principal Investigator: | Francisca Mutapi, PhD | University of Edinburgh |
More Information
Additional Information:
No publications provided
| Responsible Party: | Dr Francisca Mutapi, Dr, University of Edinburgh |
| ClinicalTrials.gov Identifier: | NCT01424410 History of Changes |
| Other Study ID Numbers: | ERI019729-THRASHER |
| Study First Received: | June 16, 2011 |
| Last Updated: | August 26, 2011 |
| Health Authority: | Zimbabwe: Medical Research Council |
Keywords provided by University of Edinburgh:
|
paediatric schistosomiasis morbidity immunology |
Additional relevant MeSH terms:
|
Schistosomiasis Trematode Infections Helminthiasis Parasitic Diseases |
ClinicalTrials.gov processed this record on May 23, 2013